Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PEGFILGRASTIM Clear all

Conditions: Neutropenia, Breast Cancer
Interventions: SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 49
States / cities: Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: ofatumumab + bendamustine; Drug
Lead sponsor: Nevada Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Gainesville, Florida • Las Vegas, Nevada

Conditions: RUNX1 Familial Platelet Disorder
Interventions: G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Breast Cancer
Interventions: Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: New York, New York

Conditions: Large B Cell Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, filgrastim, pegfilgrastim; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2021
U.S. locations: 47
States / cities: La Jolla, California • Mountain View, California • Palo Alto, California + 38 more

Conditions: Breast Cancer
Interventions: Docetaxel, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 85 more

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pegfilgrastim, carboplatin, docetaxel, erlotinib hydrochloride; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin
Interventions: XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Ponatinib, Prednisone, Rituximab, Vincristine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Filgrastim, Fludarabine, Idarubicin, Pegfilgrastim, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mantle Cell Lymphoma
Interventions: Bendamustine, Rituximab, Cytarabine, Pegfilgrastim, Leukapheresis, Filgrastim, Autologous stem cell transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Cancer
Interventions: pegfilgrastim, LY2523355; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
Interventions: Obinutuzumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib, Acetaminophen, Diphenhydramine, Peg-filgrastim, CT Scan (chest, abdomen, and pelvis), MRI, 18f-FDG-PET, PET, Lumbar puncture/Ommaya tap, Bone marrow aspiration/biopsy, EKG; Drug · Other · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia
Interventions: Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab, Filgrastim; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer
Interventions: MK-0752, Docetaxel, Pegfilgrastim; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat, Etrumadenant, Modified FOLFIRINOX; Radiation · Drug
Lead sponsor: Gulam Manji; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions: Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 201
States / cities: Phoenix, Arizona • Burbank, California • Concord, California + 138 more

Conditions: Breast Cancer, Adenocarcinoma of the Breast
Interventions: epirubicin, cyclophosphamide, Paclitaxel,; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Adriamycin and Cytoxan (AC), ABI-007, Taxol, Bevacizumab, pegfilgrastim; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Sedona, Arizona • Denver, Colorado + 23 more

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions: oblimersen sodium, rituximab, ifosfamide, carboplatin, etoposide, filgrastim, pegfilgrastim, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hodgkin Lymphoma
Interventions: Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor; Radiation · Drug
Lead sponsor: University College, London; Other
Eligibility: 16 Years to 69 Years
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 3
States / cities: Stanford, California • Miami, Florida • New York, New York

Conditions: Female Breast Cancer
Interventions: docetaxel + cyclophosphamide + pegfilgrastim; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Triple-negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more

Search by objective public record fields.

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

TAC Versus TC for Adjuvant Breast Cancer

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

A Dose-Escalation Study for Patients With Advanced Cancer

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer